文献
J-GLOBAL ID:201802284733616955
整理番号:18A0397193
進行肝細胞癌(CheckMate 040)患者におけるニボルマブ:非盲検非比較,第1/2相用量漸増と拡大試験【Powered by NICT】
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
著者 (22件):
El-Khoueiry Anthony B
(USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA)
,
Sangro Bruno
(Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain)
,
Yau Thomas
(University of Hong Kong, Hong Kong Special Administrative Region, China)
,
Crocenzi Todd S
(Providence Cancer Center, Portland, OR, USA)
,
Kudo Masatoshi
(Kindai University Faculty of Medicine, Osaka, Japan)
,
Hsu Chiun
(National Taiwan University Hospital, Taipei, Taiwan)
,
Kim Tae-You
(Seoul National University Hospital, Seoul, South Korea)
,
Choo Su-Pin
(National Cancer Center, Singapore)
,
Trojan Jorg
(Goethe University Hospital and Cancer Center, Frankfurt, Germany)
,
Welling Theodore H
(University of Michigan School of Medicine, Ann Arbor, MI, USA)
,
Meyer Tim
(Royal Free Hospital, London, UK)
,
Kang Yoon-Koo
(Asan Medical Center, University of Ulsan, Seoul, South Korea)
,
Yeo Winnie
(Chinese University of Hong Kong, Hong Kong Special Administrative Region, China)
,
Chopra Akhil
(Johns Hopkins Singapore International Medical Centre, Singapore)
,
Anderson Jeffrey
(Bristol-Myers Squibb, Princeton, NJ, USA)
,
dela Cruz Christine
(Bristol-Myers Squibb, Princeton, NJ, USA)
,
Lang Lixin
(Bristol-Myers Squibb, Princeton, NJ, USA)
,
Neely Jaclyn
(Bristol-Myers Squibb, Princeton, NJ, USA)
,
Tang Hao
(Bristol-Myers Squibb, Princeton, NJ, USA)
,
Dastani Homa B
(Bristol-Myers Squibb, Princeton, NJ, USA)
,
Melero Ignacio
(Biomedical Research Network in Oncology (CIBERONC), Pamplona, Spain)
,
Melero Ignacio
(Center for Applied Medical Research (CIMA), Pamplona, Spain)
資料名:
Lancet
(Lancet)
巻:
389
号:
10088
ページ:
2492-2502
発行年:
2017年
JST資料番号:
B0673A
ISSN:
0140-6736
CODEN:
LANCA
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)